AM2389, a high-affinity, in vivo potent CB 1-receptor-selective cannabinergic ligand as evidenced by drug discrimination in rats and hypothermia testing in mice

Psychopharmacology

Volumn 220, Issue 2, 2012, Pages 417-426

  Järbe, Torbjörn U C ^a   Tai, Sherrica ^a   LeMay, Brian J ^a   Nikas, Spyros P ^a   Shukla, Vidyanand G ^a   Zvonok, Alexander ^a   Makriyannis, Alexandros ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

9 THC; AM2389; AM251; AM5983; Cannabinoid; Drug discrimination; Hypothermia; Mice; Rats

Indexed keywords

9BETA HYDROXY 3 (1 HEXYLCYCLOBUT 1 YL)HEXAHYDROCANNABINOL; [1 [(1 METHYLPIPERIDIN 2 YL)METHYL] 1H INDOL 3 YL](NAPHTHALEN 1 YL)METHANONE; AM 2389; AM 5983; CANNABINOID 1 RECEPTOR AGONIST; DRONABINOL; NABILONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DISCRIMINATION; DRUG HALF LIFE; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; IN VIVO STUDY; INDUCED HYPOTHERMIA; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RECTUM TEMPERATURE;

ANIMALS; BENZOPYRANS; CONDITIONING, OPERANT; DISCRIMINATION (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HYPOTHERMIA; INDOLES; MALE; MICE; MICE, INBRED C57BL; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; TETRAHYDROCANNABINOL; TIME FACTORS;

EID: 84858450136     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-011-2491-1     Document Type: Article

References (47)

1. Atwood BK, Mackie K (2010) CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 160:467-479
2. Balster RL, Prescott WR (1992) A#sup#9#/sup#-Tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication. Neurosci Biobehav Rev 16:55-62
3. Bayewitch M, Avidor-Reiss T, Levy R, Barg J, Mechoulam R, Vogel Z (1995) The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett 375:143-147
4. Bergman J, France CP, Holtzman SG, Katz JL, Koek W, Stephens DN (2000) Agonist efficacy, drug dependence, and medications development: preclinical evaluation of opioid, dopaminergic, and GABAA-ergic ligands. Psychopharmacology (Berl) 153:67-84 (Pubitemid 32127905)
5. Browne RG, Weissman A (1981) Discriminative stimulus properties of A -tetrahydrocannabinol: mechanistic studies. J Clin Pharmacol 21:227S-234S
6. Carney JM, Balster RL, Martin BR, Harris LS (1979) Effects of systemic and intraventricular administration of cannabinoids on schedule-controlled responding in the squirrel monkey. J Pharmacol Exp Ther 210:399-404 (Pubitemid 10196320)
7. De Vry J, Jentzsch KR (2003) Intrinsic activity estimation of cannabinoid CB1 receptor ligands in a drug discrimination paradigm. Behav Pharmacol 14:471-476 (Pubitemid 37176805)
8. Devane WA, Breuer A, Sheskin T, Järbe TUC, Eisen MS, Mechoulam R (1992) A novel probe for the cannabinoid receptor. J Med Chem 35:2065-2069
9. Edery H, Porath G, Mechoulam R, Lander N, Srebnik M, Lewis N (1984) Activity of novel aminocannabinoids in baboons. J Med Chem 27:1370-1373 (Pubitemid 14032259)
10. Extance K, Goudie AJ (1981) Inter-animal olfactory cues in operant drug discrimination procedures in rats. Psychopharmacology (Berl) 73:363-371 (Pubitemid 11114123)
11. Ford RD, Balster RL, Dewey WL, Rosecrans JA, Harris LS (1984) The discriminative stimulus properties of A -tetrahydrocannabinol: generalization to some metabolites and congeners. In: Agurell S, Dewey WL, Willette RE (eds) The cannabinoids: chemical, pharmacologic and therapeutic aspects. Academic, New York, pp 545-561
12. Garcia-Gutierrez MS, Garcia-Bueno B, Zoppi S, Leza JC, Manzanares J (2011) Chronic blockade of cannabinoid CB(2) receptors induces anxiolytic-like actions associated to alterations in GABA(A) receptors. Br J Pharmacol. doi: 10.1111/j.1476-5381.2011.01625.x
13. Järbe TUC (1978) A -Tetrahydrocannabinol: tolerance after noncon-tingent exposure in rats. Arch Int Pharmacodyn Ther 231:49-56 (Pubitemid 8287007)
14. Järbe TUC (1989) Discrimination learning with drug stimuli: methods and applications. In: Boulten AA, Baker GB, Greenshaw AJ (eds) Neuromethods: vol. 13. Psychopharmacology. Humana, Clifton, pp 513-563
15. Järbe TUC (2011) Perceptual drug discriminative aspects of the endocannabinoid signaling system in animals and man. In: Glennon RA, Young R (eds) Drug discrimination: applications to medicinal chemistry and drug studies. Wiley, Hoboken, pp 241-285
16. Järbe TUC, Deng H, Vadivel SK, Makriyannis A (2011a) Cannabi-nergic aminoalkylindoles, including AM678=JWH018 found in 'Spice', examined using drug (A -THC) discrimination for rats. Behav Pharmacol 22:498-507
17. Järbe TUC, Harris MY, Li C, Liu Q, Makriyannis A (2004) Discriminative stimulus effects in rats of SR-141716 (rimona-bant), a cannabinoid CB1 receptor antagonist. Psychopharmacol-ogy (Berl) 177:35-45 (Pubitemid 40109912)
18. Järbe TUC, Hiltunen AJ, Lander N, Mechoulam R (1986) Cannabi-mimetic activity (delta-1-THC cue) of cannabidiol monomethyl ether and two stereoisomeric hexahydrocannabinols in rats and pigeons. Pharmacol Biochem Behav 25:393-399 (Pubitemid 16045863)
19. Järbe TUC, Hiltunen AJ, Mechoulam R (1989) Stereospecificity of the discriminative stimulus functions of the dimethylheptyl homologs of 11-hydroxy-Δ#sup#8#/sup#-tetrahydrocannabinol in rats and pigeons. J Pharmacol Exp Ther 250:1000-1005 (Pubitemid 19246712)
20. Järbe TUC, Lemay BJ, Vemuri VK, Vadivel SK, Zvonok A, Makriyannis A (2011b) Central mediation and differential blockade by cannabinergics of the discriminative stimulus effects of the cannabinoid CB(1) receptor antagonist rimonabant in rats. Psychopharmacology (Berl) 216:355-365
21. Järbe TUC, Li C, Vadivel SK, Makriyannis A (2008) Discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats. Psychopharmacology (Berl) 198:467-478
22. Järbe TUC, Liu Q, Makriyannis A (2006) Antagonism of discriminative stimulus effects of Δ#sup#9#/sup#-THC and (R)-methanandamide in rats. Psychopharmacology (Berl) 184:36-45 (Pubitemid 43005755)
23. Järbe TUC, McMillan DE (1980) Δ#sup#9#/sup#-THC as a discriminative stimulus in rats and pigeons: generalization to THC metabolites and SP-111. Psychopharmacology (Berl) 71:281-289 (Pubitemid 11194005)
24. Järbe TUC, Swedberg MD, Mechoulam R (1981) A repeated test procedure to assess onset and duration of the cue properties of (-) Δ#sup#9#/sup#- THC, (-) Δ#sup#8#/sup#-THC-DMH and (+) Δ#sup#8#/sup#-THC. Psychophar-macology (Berl) 75:152-157 (Pubitemid 12228822)
25. Lile JA, Kelly TH, Hays LR (2010) Substitution profile of the cannabinoid agonist nabilone in human subjects discriminating Δ#sup#9#/sup#- tetrahydrocannabinol. Clin Neuropharmacol 33:235-242
26. Lile JA, Kelly TH, Hays LR (2011) Separate and combined effects of the cannabinoid agonists nabilone and Δ#sup#9#/sup#-THC in humans discriminating Δ#sup#9#/sup#-THC. Drug Alcohol Depend 116:86-92
27. Lile JA, Kelly TH, Pinsky DJ, Hays LR (2009) Substitution profile of Δ#sup#9#/sup#-tetrahydrocannabinol, triazolam, hydromorphone, and meth-ylphenidate in humans discriminating Δ#sup#9#/sup#- tetrahydrocannabinol. Psychopharmacology (Berl) 203:241-250
28. McMahon LR (2006) Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Δ#sup#9#/sup#-tetrahydrocannabinol. J Pharmacol Exp Ther 319:1211-1218
29. McMahon LR (2011) Chronic Δ#sup#9#/sup#-tetrahydrocannabinol treatment in rhesus monkeys: differential tolerance and cross-tolerance among cannabinoids. Br J Pharmacol 162:1060-1073
30. McMahon LR, Koek W (2007) Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6 J mice. Eur J Pharmacol 569:70-76 (Pubitemid 47175872)
31. Nikas SP, Alapafuja SO, Papanastasiou I, Paronis CA, Shukla VG, Papahatjis DP, Bowman AL, Halikhedkar A, Han X, Makriyan-nis A (2010) Novel 1',1'-chain substituted hexahydrocannabinols: 9beta-hydroxy-3-(1-hexyl-cyclobut- 1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid receptor 1 (CB1) agonist. J Med Chem 53:6996-7010
32. Papahatjis DP, Kourouli T, Abadji V, Goutopoulos A, Makriyannis A (1998) Pharmacophoric requirements for cannabinoid side chains: multiple bond and C1'-substituted Δ#sup#8#/sup#-tetrahydrocannabi-nols. J Med Chem 41:1195-1200 (Pubitemid 28207395)
33. Papahatjis DP, Nahmias VR, Nikas SP, Andreou T, Alapafuja SO, Tsotinis A, Guo J, Fan P, Makriyannis A (2007) C1'-cycloalkyl side chain pharmacophore in tetrahydrocannabinols. J Med Chem 50:4048-4060 (Pubitemid 47301737)
34. Papahatjis DP, Nikas SP, Andreou T, Makriyannis A (2002) Novel 1',1'-chain substituted Δ#sup#8#/sup#-tetrahydrocannabinols. Bioorg Med Chem Lett 12:3583-3586
35. Papahatjis DP, Nikas SP, Kourouli T, Chari R, Xu W, Pertwee RG, Makriyannis A (2003) Pharmacophoric requirements for the cannabinoid side chain. Probing the cannabinoid receptor subsite at C1'. J Med Chem 46:3221-3229 (Pubitemid 36842408)
36. Reggio PH, McGaughey GB, Odear DF, Seltzman HH, Compton DR, Martin BR (1991) A rational search for the separation of psychoactivity and analgesia in cannabinoids. Pharmacol Bio-chem Behav 40:479-486
37. Roche M, Finn DP (2010) Brain CB2 receptors: implications for neuropsychiatric disorders. Pharmaceuticals 3:2517-2553
38. Sidman M (1960) Tactics of scientific research-evaluating experimental data in psychology. Basic Books, New York
39. Singh H, Schulze DR, McMahon LR (2011) Tolerance and cross-tolerance to cannabinoids in mice: schedule-controlled responding and hypothermia. Psychopharmacology (Berl) 215:665-675
40. Stolerman IP, Childs E, Ford MM, Grant KA (2011) Role of training dose in drug discrimination: a review. Behav Pharmacol 22:415-429
41. Tai S, Järbe TUC, LeMay B, Nikas SP, Makriyannis A (2008) In vivo characterization of AM-2389, a potent CB1R selective agonist. International Cannabinoid Research Society (ICRS), Burlington, VT
42. Tai S, Järbe TUC, Nikas SP, Makriyannis A (2011) Characterization of a CB1 receptor agonist (AM2389) with a long duration of effect to facilitate the study of CB1 dependence/withdrawal International Cannabinoid Research Society (ICRS). Burlington, VT
43. Vann RE, Cook CD, Martin BR, Wiley JL (2007) Cannabimimetic properties of ajulemic acid. J Pharmacol Exp Ther 320:678-686 (Pubitemid 46147948)
44. Weissman A (1978) Generalization of the discriminative stimulus properties of delta-9-tetrahydrocannabinol to cannabinoids with therapeutic potential. In: Colpaert FC, Rosecrans JA (eds) Stimulus properties of drugs: ten years of progress. Press, Amsterdam, Elsevier/North Holland Biomed, pp 99-122
45. Wiley JL, Matthew Walentiny D, Vann RE, Baskfield CY (2011) Dissimilar cannabinoid substitution patterns in mice trained to discriminate Δ#sup#9#/sup#-tetrahydrocannabinol or methanandamide from vehicle. Behav Pharmacol 22:480-488
46. Wilson RS, May EL, Martin BR, Dewey WL (1976) 9-Nor-9- hydroxyhexahydrocannabinols. Synthesis, some behavioral and analgesic properties, and comparison with the tetrahydrocanna-binols. J Med Chem 19:1165-1167
47. Xi ZX, Peng XQ, Li X, Song R, Zhang HY, Liu QR, Yang HJ, Bi GH, Li J, Gardner EL (2011) Brain cannabinoid CB(2) receptors modulate cocaine's actions in mice. Nat Neurosci. doi:10.1038/nn.2874